Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin

Acta Biochimica et Biophysica Sinica

Volumn 38, Issue 10, 2006, Pages 704-710

  Lei, Xiao Yong ^a   Zhong, Miao ^a   Feng, Lan Fang ^a   Zhu, Bing Yang ^a   Tang, Sheng Song ^a   Liao, Duan Fang ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

5 fluorouracil; Bcl XL; Hepg2 cells; Hydroxycamptothecin; Small interference RNA

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BCL2L1 PROTEIN, HUMAN; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; MESSENGER RNA; PROTEIN BCL X; SMALL INTERFERING RNA;

ARTICLE; BIOSYNTHESIS; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-X PROTEIN; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33750487510     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2006.00212.x     Document Type: Article

References (16)

1. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998, 281: 1322-1326
2. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001, 34: 55-61
3. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996, 56: 2422-2427
4. Foreman KE, Wrone-Smith T, Boise LH, Thompson CB, Polverini PJ, Simonian PL, Núñez G et al. Kaposi's sarcoma tumor cells preferentially express Bcl-xL. Am J Pathol 1996, 149: 795-803
5. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 1998, 58: 256-262
6. Jiang M, Milner J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 2003, 17: 832-837
7. Frankel A, Rosen K, Filmus J, Kerbel RS. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res 2001, 64: 4837-4841
8. Lei XY, Zhong M, Feng LF, Yan CY, Zhu BY, Tang SS, Liao DF. Silencing of Bcl-XL expression in human MGC-803 gastric cancer cells by siRNA. Acta Biochim Biophys Sin 2005, 37: 555-560
9. Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001, 2: 110-119
10. Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann NY Acad Sci 2003, 1002: 56-62
11. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003, 270: 1628-1644
12. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997, 57: 62-67
13. Itoh M, Chiba H, Noutomi T, Takada E, Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncol 2000, 36: 277-285
14. Solhaug A, Refsnes M, Lag M, Schwarze PE, Husoy T, Holme JA. Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. Carcinogenesis 2004, 25: 809-819
15. Erler JT, Cawthorne CJ, William KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24: 2875-2889
16. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2: 183-192